Oncology Practice Models: Academic Cancer Centers and Community Oncology

Academic cancer centers and community oncology practices represent the two primary structural frameworks through which cancer care is delivered in the United States. Understanding how these models differ — in staffing, scope, research integration, and regulatory oversight — helps clarify why a patient's care pathway may look substantially different depending on where treatment occurs. This page covers the defining characteristics of each model, how they function operationally, the clinical scenarios each serves best, and the boundaries that separate one from the other. The broader landscape of oncology practice encompasses both settings as essential, complementary components of the national cancer care infrastructure.

Definition and scope

Academic cancer centers are institutions formally integrated with medical schools or universities, typically designated by the National Cancer Institute (NCI) as either Comprehensive Cancer Centers or Cancer Centers. As of the NCI's published criteria, Comprehensive Cancer Center designation requires demonstrated research depth across at least three program areas — laboratory, clinical, and population sciences — as well as peer-reviewed cancer research funding (NCI Cancer Centers Program). There are 72 NCI-designated cancer centers across the United States as of the NCI's current registry.

Community oncology practices operate outside academic medical systems and deliver care through private group practices, hospital-affiliated outpatient clinics, or integrated health system networks. The Community Oncology Alliance (COA) tracks this sector and has documented that approximately 83% of cancer patients in the United States receive treatment in community-based settings rather than academic centers (Community Oncology Alliance).

Both model types fall under the regulatory framework administered by the Centers for Medicare & Medicaid Services (CMS), which governs billing, facility certification, and quality reporting through the Oncology Care Model and its successor programs. The regulatory context for oncology elaborates on how CMS, FDA, and state medical boards intersect with practice-level operations.

How it works

Academic cancer centers: operational structure

Academic centers function as multi-disciplinary organizations where clinical care, research, and education operate simultaneously. A patient receiving treatment at an NCI-designated Comprehensive Cancer Center may be seen by attending oncologists who hold dual faculty appointments and carry active clinical trial portfolios.

Key operational features include:

1. Multidisciplinary tumor boards — structured case conferences involving surgical, medical, and radiation oncologists, radiologists, pathologists, and subspecialty nurses reviewing complex cases before treatment begins.
2. On-site clinical trial access — academic centers maintain Investigational New Drug (IND) applications through the FDA and operate under Institutional Review Board (IRB) oversight for human subjects research (45 CFR Part 46).
3. Subspecialty depth — faculty-level specialists in rare malignancies (e.g., ocular melanoma, adrenocortical carcinoma) are concentrated at academic centers where case volume justifies the specialization.
4. Pathology and genomics infrastructure — in-house molecular profiling laboratories capable of next-generation sequencing panels, often without the 2–4 week send-out delays common in community settings.

Community oncology: operational structure

Community practices prioritize geographic accessibility and clinical efficiency for standard-of-care treatment delivery. A typical community oncology group operates infusion suites, manages oral oncolytics, and coordinates with local hospital radiology and surgery departments rather than housing all services under one roof.

Key operational features include:

1. Proximity to patients — community clinics are distributed across suburban and rural regions where NCI-designated centers do not exist, reducing the travel burden that affects treatment adherence.
2. ASCO and NCCN guideline adherence — community oncologists follow National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines, which are updated at least annually across 60+ cancer types (NCCN).
3. CMS quality reporting — participation in CMS's Merit-based Incentive Payment System (MIPS) or alternative payment models (APMs) is a standard compliance requirement.
4. Referral network relationships — complex or refractory cases are escalated to academic centers through established referral agreements.

Common scenarios

Scenarios favoring academic center care:

• Rare or poorly characterized malignancies with limited published treatment data
• Cases requiring phase I or phase II clinical trial enrollment unavailable in community settings
• Cases requiring bone marrow or stem cell transplantation, which demands transplant program infrastructure
• Surgical oncology procedures with low national case volume, such as cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC)
• Patients with conflicting pathology findings seeking formal second opinions

Scenarios favoring community oncology care:

• Standard-line chemotherapy or immunotherapy for common malignancies (e.g., Stage II–III non-small cell lung cancer, hormone receptor-positive breast cancer)
• Patients with limited mobility or transportation access for whom a 100-mile academic center drive creates a compliance barrier
• Ongoing maintenance or surveillance care following initial treatment at an academic center
• Patients whose primary oncologist has reached a clear diagnosis via molecular profiling and biomarker testing and a defined NCCN-concordant regimen exists

Decision boundaries

The distinction between the two models is not simply prestige — it is functional scope. Three structured boundaries define where one model ends and the other begins:

1. Clinical trial availability
Academic centers hold the infrastructure for early-phase trials. Community practices predominantly participate in phase III cooperative group trials through networks such as the SWOG Cancer Research Network or the Alliance for Clinical Trials in Oncology, not phase I dose-escalation studies.

2. Subspecialty concentration
Conditions with fewer than 10,000 U.S. cases annually — such as malignant pleural mesothelioma or primary peritoneal carcinoma — lack the community case volume to support specialist depth. NCI-designated centers accumulate sufficient case numbers to develop institutional expertise.

3. Regulatory and billing classification
Hospitals that house academic cancer centers bill as hospital outpatient departments under CMS's Outpatient Prospective Payment System (OPPS), while freestanding community oncology practices bill under the Physician Fee Schedule. This structural difference affects drug reimbursement through the 340B Drug Pricing Program, which applies to eligible nonprofit and government hospitals but not to independent physician-owned community practices.

Patients moving between models — for example, initiating care at a community practice and transferring to an academic center for a clinical trial — typically maintain continuity through shared electronic health records and coordinated tumor board documentation, though interoperability gaps remain a recognized challenge under the 21st Century Cures Act's information-blocking provisions.

References

• NCI Cancer Centers Program — Designation Criteria and Center List
• Community Oncology Alliance — Community Oncology Practice Data
• National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines
• CMS Oncology Care Model and Merit-based Incentive Payment System (MIPS)
• FDA Investigational New Drug Application — 21 CFR Part 312
• HHS 45 CFR Part 46 — Protection of Human Subjects (Common Rule)
• 21st Century Cures Act — Information Blocking Provisions (ONC)
• SWOG Cancer Research Network
• Alliance for Clinical Trials in Oncology

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)